Quantification of human lithostathine S2-5 forms using the antibody to the N-terminal peptide region.
Lithostathine S2-5 inhibits in vitro crystal growth of CaCO3. We developed an antibody against the peptide region responsible for inhibitory effect to determine whether lithostathine S2-5 levels are different in the pancreatic juice of patients with and without chronic pancreatitis. The antibody against the synthetic peptide of the N-terminal end of lithostathine S2-5 detected lithostathine S2-5 but not lithostathine S1 or lithostathine extracted from pancreatic calculi. Lithostathine S2-5 was detected in samples of pancreatic juice protein by immunoblotting using the specific antibody. The concentration of lithostathine S2-5 was compared between control and chronic pancreatitis groups. The mean concentrations of lithostathine S2-5 were significantly (p=0.002) lower in chronic pancreatitis, 16.3 microg/mg of total protein, than in the control, 47.1 microg/mg of total protein. A decreased concentration of lithostathine S2-5 seems to increase the risk of stone formation in the ducts during the course of chronic pancreatitis because of insufficient inhibition of CaCO3 crystal growth.
Yamadera
K
K
Second Department of Internal Medicine, Asahikawa Medical College, Japan.
Wada
K
K
Goto
M
M
Yokoyama
K
K
Morita
Y
Y
Kitano
Y
Y
Makino
I
I
D000328:Adult; D000368:Aged; D002135:Calcium-Binding Proteins / Q000032:analysis* / Q000276:immunology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D051847:Lithostathine; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins; D010189:Pancreatic Juice / Q000737:chemistry; D010195:Pancreatitis / Q000378:metabolism*
D002135:Calcium-Binding Proteins; D051847:Lithostathine; D009419:Nerve Tissue Proteins; C497617:REG1A protein, human